Literature DB >> 11495346

Subchronic treatment with methamphetamine and phencyclidine differentially alters the adenosine A1 and A2A receptors in the prefrontal cortex, hippocampus, and striatum of the rat.

Y Shirayama1, K Hashimoto, T Higuchi, Y Minabe.   

Abstract

Subchronic treatment with MAP (4.6 mg/kg, i.p., once daily for 11 days) significantly decreased the Kd, but not Bmax, values of [3H]1,3-dipropyl-8-cyclopentylxanthine ([3H]DPCPX) binding to adenosine A1 receptors in the prefrontal cortex and hippocampus, but not striatum, of rat brain. However, subchronic treatment with PCP (10 mg/kg, i.p., once daily for 11 days) did not alter the Kd and Bmax values of [3H]DPCPX binding to adenosine A1 receptors in these three regions. Subchronic treatment with MAP or PCP did not alter the Bmax and Kd values of [3H]2-p-(2-carboxyehyl)phenethylamino-5'-N-ethylcarboxyamidoadenosine ([3H]CGS21680) binding to adenosine A2A receptors in the striatum. Furthermore, subchronic treatment with MAP or PCP significantly decreased the specific binding of [3H]CGS21680 to adenosine A2A receptors in the hippocampus, but not in the prefrontal cortex. Thus, these results suggest that MAP and PCP may produce differential effects on the adenosine A2A receptors, but not adenosine A1 receptors in rat brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11495346     DOI: 10.1023/a:1010994913749

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  41 in total

1.  The adenosine A1 receptor agonist N6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat.

Authors:  T L Sills; A Azampanah; P J Fletcher
Journal:  Eur J Pharmacol       Date:  1999-03-26       Impact factor: 4.432

2.  Adenosine A2 receptors modulate hippocampal synaptic transmission via a cyclic-AMP-dependent pathway.

Authors:  K Kessey; D J Mogul
Journal:  Neuroscience       Date:  1998-05       Impact factor: 3.590

3.  Alterations in striatal dopamine overflow during rotational behavior induced by amphetamine, phencyclidine, and MK-801.

Authors:  A Mele; D Fontana; A Pert
Journal:  Synapse       Date:  1997-07       Impact factor: 2.562

4.  Stereoselective antagonism of phencyclidine's discriminative properties by adenosine receptor agonists.

Authors:  R G Browne; W M Welch
Journal:  Science       Date:  1982-09-17       Impact factor: 47.728

5.  Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers.

Authors:  A Breier; A K Malhotra; D A Pinals; N I Weisenfeld; D Pickar
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

6.  Binding of [3H]KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membranes.

Authors:  H Nonaka; A Mori; M Ichimura; T Shindou; K Yanagawa; J Shimada; H Kase
Journal:  Mol Pharmacol       Date:  1994-11       Impact factor: 4.436

7.  Neuroleptics up-regulate adenosine A2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia.

Authors:  B Parsons; D M Togasaki; S Kassir; S Przedborski
Journal:  J Neurochem       Date:  1995-11       Impact factor: 5.372

8.  Excitatory and inhibitory effects of A1 and A2A adenosine receptor activation on the electrically evoked [3H]acetylcholine release from different areas of the rat hippocampus.

Authors:  R A Cunha; E Milusheva; E S Vizi; J A Ribeiro; A M Sebastião
Journal:  J Neurochem       Date:  1994-07       Impact factor: 5.372

9.  A1 adenosine receptors of bovine brain couple to guanine nucleotide-binding proteins Gi1, Gi2, and Go.

Authors:  R Munshi; I H Pang; P C Sternweis; J Linden
Journal:  J Biol Chem       Date:  1991-11-25       Impact factor: 5.157

10.  An increase in [3H] CGS21680 binding in the striatum of postmortem brains of chronic schizophrenics.

Authors:  A Kurumaji; M Toru
Journal:  Brain Res       Date:  1998-10-19       Impact factor: 3.252

View more
  1 in total

1.  Role of adenosine receptor subtypes in methamphetamine reward and reinforcement.

Authors:  Kevin A Kavanagh; Drew C Schreiner; Sophia C Levis; Casey E O'Neill; Ryan K Bachtell
Journal:  Neuropharmacology       Date:  2014-10-06       Impact factor: 5.250

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.